News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galena Biopharma  (GALE) Gives Sales Team Another Useless Product To Promote



7/23/2014 6:03:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Galena BioPharma (GALE) CEO Mark Ahn continues to shell out big money for obsolete, rarely prescribed drug products. Tuesday, Galena entered into a license agreement with MonoSol Rx for Zuplenz, an oral dissolvable film containing ondansetron, a drug approved to treat nausea and vomiting caused by cancer chemotherapy. Galena is paying $5 million in cash and stock for U.S. marketing rights to Zuplenz. Galena will also owe MonoSol double-digit royalties on Zuplenz net sales, if any accrue.

Hey, check out all the research scientist jobs. Post your resume today!

Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES